AIM ImmunoTech
Ocala, United States · Biotechnology, Healthcare, Health Care
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical tr
Key facts
- Headquarters
- Ocala, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (AIM)
- Website
- aimimmuno.com
- Company page
Recent activity at AIM ImmunoTech
- : SEC 8-K (1.01): On September 8-9, 2026, AIM ImmunoTech Inc. entered into two exchange agreements with Streeterville Capital, LLC. These agreements enabled the conversion of approximately $400,000 of a previously issued promissory note into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. This transaction was previously approved by the Company’s stockholders, aligning with compliance procedures under NYSE American regulations. The strategic implication of this conversion is expected to enhance liquidity and balance the Company’s capital structure effectively.
- : AIM ImmunoTech Secures $400,000 Through Exchange Agreements
- : SEC 8-K (1.01): On September 3, 2026, AIM ImmunoTech Inc. entered into two exchange agreements with Streeterville Capital, LLC. These agreements involved the conversion of approximately $450,000 of a previously issued Promissory Note into 1,921,441 shares of the company's common stock at an average conversion price of $0.234 per share. Shareholder approval for this conversion was obtained prior, ensuring compliance with NYSE American requirements. The transaction will potentially enhance the company’s equity base and strengthen its financial position in light of future operational needs.
- : SEC 8-K (1.01): On August 31, 2026, AIM ImmunoTech Inc. entered into five exchange agreements with Streeterville Capital, LLC, which involved the conversion of approximately $1,224,341 of a prior Promissory Note dated February 16, 2024 into 5,065,840 shares of the Company's common stock at an average conversion price of approximately $0.24 per share. The conversion satisfied the Promissory Note in full, eliminating any remaining obligations. The agreements reflect a significant restructuring of the Company's debt and enhance its equity position as of September 3, 2026.
- : AIM Immunotech Converts Debt to Equity, Raises Over $1.2 Million
- : AIM ImmunoTech Inc. announces a registered direct offering and private placement, raising approximately $2.4 million. The company plans to use the funds for drug supply, clinical trials, and working capital.
- : AIM ImmunoTech Inc. Enters Warrant Agency Agreement
- : SEC 8-K (1.01): On March 6, 2026, AIM ImmunoTech Inc. entered into a Warrant Agency Agreement with Equiniti Trust Company, LLC in connection with the closing of its previously announced Rights Offering. This agreement designates EQ as the warrant agent for the warrants included in the units issued during this offering. The strategic implications of this agreement are significant as they formalize the management of the warrants, enhancing the structure of the fundraised capital and ensuring compliance with securities regulations. The agreement bolsters investor confidence in the transaction which took place on March 4 and 6, 2026, outlining the roles and responsibilities of the involved parties in managing the warrants effectively.
- : SEC 8-K (5.07): On December 16, 2025, AIM ImmunoTech Inc. held its 2025 Annual Meeting of Stockholders. The meeting involved key votes on various matters, with 1,144,383 shares (41.4% of the outstanding shares) represented. Details of the voting matters were further described in the definitive proxy statement filed on November 4, 2025. The meeting facilitated engagement with shareholders and was crucial for governance decisions affecting the company's direction and operations.
- : AIM ImmunoTech Inc. announces participation in a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp to discuss Ampligen®
AIM ImmunoTech funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Debt Financing | $400K |
| Aug 2026 | Seed | $1.2M |
| May 2026 | Seed | $2.4M |
| Feb 2024 | Seed | $3.3M |
| Feb 2024 | Seed | $3.3M |
Leadership
- David, Member Board of Directors
- Jodie, Director of Accounting & Finance
- Ann, Director of Human Resources and Administration; Deputy Investor Relations Coordinator
- Stewart Appelrouth, Director
- William Mitchell, Director
- Thomas Equels, Executive Officer, Director
- Stewart Appelrouth, Director
- William Mitchell, Director
- Thomas Equels, Executive Officer, Director
- Stewart Appelrouth, Director
- Peter Rodino, Director
- William Mitchell, Director
Verified email and direct lines for AIM ImmunoTech’s decision-makers are on Fundz. See plans
Employee benefit plans
AIM ImmunoTech files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
AIM ImmunoTech in the news
- AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod - GlobeNewswire (Aug 31, 2026)
- AIM ImmunoTech Posts Virtual Investor Key Opinion Leader - GlobeNewswire (May 14, 2026)
- AIM ImmunoTech CEO Highlights Biodefense and Military Force - GlobeNewswire (Aug 12, 2026)
- AIM ImmunoTech Signs Agreement for Planning of a Proposed - GlobeNewswire (Mar 02, 2026)
- AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewswire (Jun 08, 2026)
- AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire (Sep 09, 2026)
- AIM ImmunoTech Highlights Ampligen’s Potential Role in the - GlobeNewswire (Sep 22, 2026)
- AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - GlobeNewswire (Sep 02, 2026)
Companies similar to AIM ImmunoTech
- EyePoint Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- AbbVie Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Olema Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Milestone Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Imago BioSciences, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About AIM ImmunoTech: questions and answers
What does AIM ImmunoTech do?
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical tr
Where is AIM ImmunoTech headquartered?
AIM ImmunoTech is headquartered in Ocala, United States.
Has AIM ImmunoTech raised funding?
Yes. Fundz has recorded 5 funding events for AIM ImmunoTech. The most recent, Debt Financing of $400K, was in Sep 2026.
What is the latest news on AIM ImmunoTech?
On Sep 08, 2026, SEC 8-K (1.01): On September 8-9, 2026, AIM ImmunoTech Inc. entered into two exchange agreements with Streeterville Capital, LLC. These agreements enabled the conversion of approximately $400,000 of a previously issued promissory note into 1,749,434 shares of common stock at an average conversion pr
Is AIM ImmunoTech a public company?
Yes. AIM ImmunoTech is publicly traded under the ticker AIM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy